After Pfizer’s Ibrance failed a crucial study in HR-positive, HR-negative postsurgery breast cancer patients, the company clung to hope that it could still show a benefit in a high-risk subset of those patients. But new data have officially snuffed out those hopes. There’s “no saving adjuvant for Ibrance,” SVB Leerink analyst Geoffrey Porges wrote in… Read More »
Late to the party against its SGLT2 diabetes rivals, Merck & Co.’s Steglatro has also tracked way behind in the class’ growing presence in heart failure. Now, the drugmaker has posted new data showing Steglatro could, in fact, show benefits in that indication—but it’s a limited window into the future. Steglatro cut heart failure patients’ risk… Read More »
Alana Prisco FINDINGS A UCLA-led study revealed a new way to predict which patients with “stable” heart failure — those who have heart injury but do not require hospitalization — have a higher risk of dying within one to three years. Although people with stable heart failure have similar characteristics, some have rapid disease progression… Read More »
End stage renal failure, your appetite will improve so meds new kidney will break what insulin better than your injured one. In Type 2, your kidneys cannot clean your blood properly. Medications save and improve lives — is a disease in which your body does not make enough insulin or failure use normal cause of… Read More »